Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
- 1 October 2010
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 139 (4) , 1267-1276.e4
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The complex interrelationships between chronic lung and liver disease: a reviewJournal of Viral Hepatitis, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Interferon signaling and treatment outcome in chronic hepatitis CProceedings of the National Academy of Sciences, 2008
- Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis CNature Biotechnology, 2007
- Comparison of low‐dose pegylated interferon versus standard high‐dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: An Indian experienceJournal of Gastroenterology and Hepatology, 2007
- A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut, 2007
- A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patientsJournal of Hepatology, 2006
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- An Algorithm for the Grading of Activity in Chronic Hepatitis CHepatology, 1996